50results about "Mucins" patented technology

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

To provide anti-MUC16 antibodies and uses thereof.SOLUTION: Provided herein are a composition, a method and use related to an antibody that immunospecifically binds to a glycosylated form of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating or preventing disorders, such as cancer. Provided are antibodies or antigen binding fragments thereof, and polypeptides including such antibodies or antigen-binding fragments thereof, for example, fusion proteins, conjugates, and / or chimeric antigen receptors as well as cells expressing the same.SELECTED DRAWING: Figure 1A-B

A device is provided for detecting enzymatic activity in mucus layer. The device comprises at least one mucin molecule corresponding to an enzyme of a first type, wherein the mucin molecule is coupled to a surface of the device and is configured to be in contact with mucus layer contents, at least one probe coupled to an end of the mucin molecule opposite to the surface of the device, and a detector configured to detect a presence of the probe and / or a property of the probe in order to detect a status of the mucin molecule.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The present invention relates to a purified, biocompatible mucus, which has the ability to form a gel. The mucus of the invention may be provided in a tissue model, with a cell population. The mucin or tissue model of the invention may be useful in an in vitro model of digestion, mucus permeation and / or epithelial transport.

The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and / or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.

An oligonucleotide comprising a lipophilic monomer and a use thereof in non-liver delivery. Specifically, the present disclosure relates to an oligonucleotide, comprising an antisense strand complementary to a target gene, a sense strand complementary to the antisense strand, and one or more compounds represented by formula (I). The present disclosure further relates to a pharmaceutical composition comprising the oligonucleotide, and a medicinal use of the oligonucleotide and / or the pharmaceutical composition.

An anti-tumor fusion protein that can inhibit the growth of MUC1-positive tumor cells and can inhibit the growth of tumor cells in pancreatic cancer. This fusion protein has broad application prospects for the prevention and / or treatment of pancreatic cancer.

The present disclosure relates to chimeric Tim receptors, host cells modified to include chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

The present disclosure relates to chimeric Tim4 receptors, host cells modified to include chimeric Tim4 receptor molecules, and methods of making and using such receptor molecules and modified cells.

Provided herein are compositions, methods, and uses relating to antibodies that immunospecifically bind to glycosylated forms of MUC16, a tethered mucin. Also provided herein are uses and methods for managing, treating, or preventing a disease, e.g., cancer.

The invention discloses a method for heterologous expression of snail-derived mucoprotein and application of the snail-derived mucoprotein. The snail-source mucoprotein is derived from African large snails, and the amino acid sequence of the snail-source mucoprotein is shown as SEQ ID NO.1. The protein is expressed and fermented by pichia pastoris, and the yield is obviously improved by optimizing a signal peptide sequence and a purification method and can reach 5g / L or above; and the mucoprotein with the purity of more than 95% is obtained. The snail-derived mucoprotein is subjected to efficacy characterization in vitro and on the cellular level, and the result shows that the protein has a remarkable effect in the aspect of repairing and further has the effects of resisting oxidation, relieving, moisturizing and whitening. The method can be used as a substitute of existing snail mucus, and solves the problems that snail mucus extraction is difficult in large-scale production, large in batch difference, high in pathogen pollution risk, inconsistent with the animal welfare principle and the like. Therefore, the invention has great application potential in the aspects of cosmetics, medicines and the like.

Provided are compositions and methods related to modified lubricins, methods of making the modified lubricins, and methods of using the modified lubricins for coating a variety of inanimate objects, and for prophylaxis and / or therapy of disorders where enhanced lubrication of one or more parts of a human or non-human mammal is desirable.

Disclosed are compositions comprising glycopeptides obtained from gastrointestinal mucins that have superior microbiota affects, and methods of manufacture and use thereof. Such compositions are advantageous for pharmaceutical, food stuff and pet food applications.

The present invention provides a fusion protein with high repair ability, a preparation method thereof and an application thereof, belonging to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is as shown in SEQ ID NO.1. The fusion protein is obtained by sequentially connecting the following modules in series: functional domain 1 of fibronectin, hydrophilic region 1 of elastin, functional domain 1 of mussel adhesive protein, hydrophilic region 2 of elastin, functional domain 2 of fibronectin, hydrophilic region 3 of elastin, functional domain 2 of mussel adhesive protein, hydrophilic region 4 of elastin, and integrin-binding region of elastin. The present invention constructs a fusion protein of fibronectin, elastin and mussel adhesive protein, optimizes the nucleotide sequence of the fusion protein, can significantly improve the relative migration rate of keratinocytes, increase the expression level of repair-related genes of HaCat cells, reduce the secretion amount of skin irritation factors, increase the inhibition rate of hyaluronidase, and improve skin repair and soothing ability.

The present disclosure relates to chimeric Tim receptors, host cells modified to contain chimeric Tim receptor molecules, and methods of making and using such receptor molecules and modified cells.

Disclosed is a composition of matter and a method for using that composition to treat, e.g., cancer or inflammatory joint disease. The composition is a soluble recombinant human podoplanin receptor (srhPDPN) that includes a first amino acid sequence at least 95% homologous to SEQ ID NO: 1. The srhPDPN may include a tag peptide or polypeptide (such as a polyhistidine tag) fused to the first amino acid sequence. The srhPDPN may include a signal peptide fused to the first amino acid sequence. The signal peptide may include an amino acid sequence at least 95% homologous to SEQ ID NO:2. A plurality of threonine residues of the srhPDPN may be glycosylated with sialic acid moi eties, and in some embodiments, 17 threonine residues of the srhPDPN glycosylated with sialic acid moieties. Treatments may include allowing the composition to act as a decoy receptor or ligand trap to inhibit PDPN signaling.

The present disclosure relates to oligonucleotides comprising lipophilic monomers and their use in non-liver delivery. Specifically, the present disclosure relates to oligonucleotides comprising an antisense strand complementary to a target gene, a sense strand complementary to the antisense strand, and one or more compounds represented by formula (I). The present disclosure further relates to pharmaceutical compositions comprising the oligonucleotides, and pharmaceutical uses of the oligonucleotides and / or pharmaceutical compositions.

Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and / or by a CD8+ T cell receptor. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various aspects, the cationic lipid is R-DOTAP. The invention also provides methods of use of the multiepitope peptides and of the compositions and vaccine compositions. The methods of use include methods of treating cancer and method of inducing a MUC-specific polyfunctional cytolytic T cell response in a subject.

The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.

A device (100) is provided for detecting enzymatic activity in mucus layer. The device comprises at least one mucin molecule (103) corresponding to an enzyme of a first type, wherein the mucin molecule (103) is coupled to a surface (102) of the device and is configured to be in contact with mucus layer contents, at least one probe (104) coupled to an end of the mucin molecule (103) opposite to the surface (102) of the device, and a detector (101) configured to detect a presence of the probe (104) and / or a property of the probe (104) in order to detect a status of the mucin molecule (103).